Targets › CD133
2 programs from 2 companies in 2 trials: 2 Phase 1; Hematology, Oncology; next expected readout Apr 2027.
Open in Phaseline: the race on CD133, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Omidubicel (formerly CordIn) Ex vivo expanded umbilical cord blood-derived CD133+ stem and progenitor cells | CD133 | Phase 1 | Severe Aplastic Anemia | Apr 2027 |
| Tasly Pharmaceuticals | P134 cells CD44/CD133 dual-targeting CAR-T cells | CD44, CD133 | Phase 1 | Recurrent Glioblastoma IDH Wildtype | Feb 2028 |
Severe Aplastic Anemia (1) Recurrent Glioblastoma IDH Wildtype (1)
other (2)
National Heart, Lung, and Blood Institute (NHLBI) (1) Tasly Pharmaceuticals (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.